Liver Cancer Market Report 2026

The liver cancer market size has grown rapidly in recent years. It will grow from $3.34 billion in 2025 to $3.81 billion in 2026 at a compound annual growth rate (CAGR) of 14%. The growth in the historic period can be attributed to high prevalence of hepatitis b and c infections, increasing rates of liver cirrhosis, long-term alcohol consumption patterns, limited early-stage diagnosis rates, historical reliance on surgery and chemotherapy.

The liver cancer market size is expected to see rapid growth in the next few years. It will grow to $6.39 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to rising burden of NAFLD and metabolic disorders, growing adoption of immunotherapy, increasing investment in oncology research, expanding access to advanced diagnostic tools, rising awareness of liver cancer risk factors. Major trends in the forecast period include rising incidence of hepatocellular carcinoma, growing emphasis on early detection and screening, increasing adoption of targeted and immunotherapies, expansion of multimodal treatment approaches, rising demand for specialized liver cancer care centers.

The increase in alcohol consumption is expected to propel the growth of the liver cancer market going forward. Alcohol consumption refers to the intake of alcoholic beverages, typically measured in terms of quantity and frequency. People are increasingly consuming alcohol because it helps them unwind from daily stress, fosters social connections in gatherings, and enhances moments of relaxation, while also being widely promoted through media and becoming more accessible in various settings. Excessive alcohol consumption can lead to liver cirrhosis, inflammation, and DNA damage, increasing the risk of liver cancer by promoting abnormal cell growth. For instance, in April 2024, according to the National Drugs Library, an Ireland-based data collection organization, the average annual alcohol consumption per person aged 15 years and over in 2023 was 9.9 litres of pure alcohol Additionally, 30% of people aged 15 years and over abstained from alcohol in 2022. Therefore, increasing alcohol consumption drives the liver cancer market.

Major companies operating in the liver cancer market are focusing on developing innovative therapy devices, providing transcatheter arterial chemoembolization (TACE), to enhance treatment precision, improve patient outcomes, and reduce side effects. Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure that delivers chemotherapy directly to a liver tumor while blocking its blood supply to enhance treatment effectiveness. For instance, in November 2023, Terumo Corporation, a Japan-based medical technology company, has launched Occlusafe and LifePearl, innovative therapy devices for management of liver cancer. These devices are designed to enhance the management of liver cancer, particularly hepatocellular carcinoma (HCC), which is the most common form of primary liver cancer in India, with over 20,000 new cases reported annually. Occlusafe is part of an advanced therapy called Balloon-TACE (B-TACE), which enhances the precision and effectiveness of TACE by using a balloon to occlude blood flow during the procedure. LifePearl are polyethylene glycol (PEG) embolization microspheres that can be loaded with chemotherapeutic agents.

In August 2023, TriSalus Life Sciences, Inc., a US-based oncology-focused medical technology company, merged with MedTech Acquisition Corporation. This merger aims to bolster TriSalus Life Sciences' cash reserves and support the development of innovative treatments for liver and pancreatic tumors. MedTech Acquisition Corporation is a US-based special purpose acquisition company (SPAC) that focuses on acquiring and merging with existing medical technology companies.

Major companies operating in the liver cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Terumo Corporation, Eisai Co. Ltd., Qiagen N.V., Exelixis Inc., BeiGene Ltd., RayzeBio Inc., Innovent Biologics Inc., Celsion Corporation.

North America was the largest region in the liver cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liver cancer market by increasing costs associated with imported oncology drugs, diagnostic equipment, and advanced medical devices used in treatment and staging. These effects are more pronounced across targeted therapy and immunotherapy segments, particularly in regions such as asia-pacific and europe that rely on global pharmaceutical and device supply chains. Hospitals and specialty clinics face higher treatment and procurement costs due to tariff pressures. However, tariffs have also encouraged local manufacturing, regional drug development, and diversification of supply sources, supporting long-term market resilience.

The liver cancer market research report is one of a series of new reports that provides liver cancer market statistics, including liver cancer industry global market size, regional shares, competitors with a liver cancer market share, detailed liver cancer market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer industry. This liver cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver cancer is a malignant disease that originates in the liver cells, primarily hepatocytes, and can spread to other organs. It is associated with risk factors such as chronic hepatitis B and C infections, cirrhosis, excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). The disease is often diagnosed at advanced stages, making early detection and treatment crucial for improving survival rates.

The main types of liver cancer are hepatoblastoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and fibrolamellar carcinoma. Hepatoblastoma is a rare type of liver cancer that primarily affects young children and originates from immature liver cells. Liver cancer progresses through different stages, including the early stage, intermediate stage, and advanced stage. It is treated using various methods such as targeted therapy, radiation therapy, surgery, chemotherapy, and immunotherapy. The key end users include hospitals, specialty clinics, ambulatory surgical centers, and cancer research institutes.

The liver cancer market consists of revenues earned by entities providing services such as early screening, palliative care, liver transplantation, personalized medicine, and radiofrequency ablation. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer market also includes sales of diagnostic imaging equipment, biomarker tests, embolization devices, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.